α-Actinin-3 deficiency is associated with reduced bone mass in human and mouse

Bone

Volumn 49, Issue 4, 2011, Pages 790-798

  Yang, Nan ^a,b   Schindeler, Aaron ^a,b   McDonald, Michelle M ^a   Seto, Jane T ^a,b   Houweling, Peter J ^a   Lek, Monkol ^a,b   Hogarth, Marshall ^a,b   Morse, Alyson R ^a   Raftery, Joanna M ^a   Balasuriya, Dominic ^a   MacArthur, Daniel G ^c   Berman, Yemima ^a,b   Quinlan, Kate G R ^a,b   Eisman, John A ^d   Nguyen, Tuan V ^d   Center, Jacqueline R ^d   Prince, Richard L ^e,f   Wilson, Scott G ^e,f   Zhu, Kathy ^e,f   Little, David G ^a,b   North, Kathryn N ^a,b   more..

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

ACTN3; BMD; Bone mass; R577X

Indexed keywords

ALPHA ACTININ 2; ALPHA ACTININ 3;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; CORTICAL BONE; ENPP1 GENE; FEMALE; FEMUR; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOSS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICRO-COMPUTED TOMOGRAPHY; MICROARRAY ANALYSIS; MORPHOMETRICS; MOUSE; NONHUMAN; OPG GENE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; POSTMENOPAUSE; TRABECULAR BONE; WNT7B GENE;

ABSORPTIOMETRY, PHOTON; ACTININ; ADOLESCENT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANIMALS; BONE AND BONES; BONE DENSITY; BONE MARROW CELLS; BONE RESORPTION; COHORT STUDIES; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MIDDLE AGED; ORGAN SIZE; OSTEOGENESIS; STEM CELLS; STROMAL CELLS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80052286980     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.07.009     Document Type: Article

References (53)

1. Kanis J., Melton L., Christiansen C., Johnston C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994, 9:1137-1141.
2. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
3. Deng H.W., Chen W.M., Conway T., Zhou Y., Davies K.M., Stegman M.R., et al. Determination of bone mineral density of the hip and spine in human pedigrees by genetic and life-style factors. Genet Epidemiol 2000, 19:160-177.
4. Ng M.Y.M., Sham P.C., Paterson A.D., Chan V., Kung A.W.C. Effect of environmental factors and gender on the heritability of bone mineral density and bone size. Ann Hum Genet 2006, 70:428-438.
5. Recker R.R., Deng H.-W. Role of genetics in osteoporosis. Endocrine 2002, 17:55-66.
6. Stewart A., Reid D.M. Quantitative ultrasound or clinical risk factors-which best identifies women at risk of osteoporosis?. Br J Radiol 2000, 73:165-171.
7. Tabensky A., Duan Y., Edmonds J., Seeman E. The contribution of reduced peak accrual of bone and age-related bone loss to osteoporosis at the spine and hip: insights from the daughters of women with vertebral or hip fractures. J Bone Miner Res 2001, 16:1101-1107.
8. Richards J.B., Rivadeneira F., Inouye M., Pastinen T.M., Soranzo N., Wilson S.G., et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 2008, 371:1505-1512.
9. Styrkarsdottir U., Halldorsson B.V., Gretarsdottir S., Gudbjartsson D.F., Walters G.B., Ingvarsson T., et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008, 358:2355-2365.
10. Styrkarsdottir U., Halldorsson B.V., Gretarsdottir S., Gudbjartsson D.F., Walters G.B., Ingvarsson T., et al. New sequence variants associated with bone mineral density. Nat Genet 2009, 41:15-17.
11. Rivadeneira F., Styrkarsdottir U., Estrada K., Halldorsson B.V., Hsu Y.-H., Richards J.B., et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009, 41:1199-1206.
12. Ellies D.L., Viviano B., McCarthy J., Rey J.-P., Itasaki N., Saunders S., et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 2006, 21:1738-1749.
13. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F., Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 15:457-475.
14. Richards J.B., Kavvoura F.K., Rivadeneira F., Styrkarsdottir U., Estrada K., Halldorsson B.V., et al. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med 2009, 151:528-537.
15. Blanchard A., Ohanian V., Critchley D. The structure and function of alpha-actinin. J Muscle Res Cell Motil 1989, 10:280-289.
16. Beggs A.H., Byers T.J., Knoll J.H., Boyce F.M., Bruns G.A., Kunkel L.M. Cloning and characterization of two human skeletal muscle alpha-actinin genes located on chromosomes 1 and 11. J Biol Chem 1992, 267:9281-9288.
17. North K.N., Yang N., Wattanasirichaigoon D., Mills M., Easteal S., Beggs A.H. A common nonsense mutation results in alpha-actinin-3 deficiency in the general population. Nat Genet 1999, 21:353-354.
18. Mills M., Yang N., Weinberger R., Vander Woude D.L., Beggs A.H., Easteal S., et al. Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: implications for the evolution of functional redundancy. Hum Mol Genet 2001, 10:1335-1346.
19. Yang N., MacArthur D.G., Wolde B., Onywera V.O., Boit M.K., Lau S.Y.M.-A., et al. The ACTN3 R577X polymorphism in East and West African athletes. Med Sci Sports Exerc 2007, 39:1985-1988.
20. Yang N., MacArthur D.G., Gulbin J.P., Hahn A.G., Beggs A.H., Easteal S., et al. ACTN3 genotype is associated with human elite athletic performance. Am J Hum Genet 2003, 73:627-631.
21. Moran C.N., Yang N., Bailey M.E.S., Tsiokanos A., Jamurtas A., MacArthur D.G., et al. Association analysis of the ACTN3 R577X polymorphism and complex quantitative body composition and performance phenotypes in adolescent Greeks. Eur J Hum Genet 2007, 15:88-93.
22. MacArthur D.G., Seto J.T., Raftery J.M., Quinlan K.G., Huttley G.A., Hook J.W., et al. Loss of ACTN3 gene function alters mouse muscle metabolism and shows evidence of positive selection in humans. Nat Genet 2007, 39:1261-1265.
23. Chan S., Seto J.T., MacArthur D.G., Yang N., North K.N., Head S.I. A gene for speed: contractile properties of isolated whole EDL muscle from an alpha-actinin-3 knockout mouse. Am J Physiol Cell Physiol 2008, 295:C897-C904.
24. MacArthur D.G., Seto J.T., Chan S., Quinlan K.G.R., Raftery J.M., Turner N., et al. An Actn3 knockout mouse provides mechanistic insights into the association between alpha-actinin-3 deficiency and human athletic performance. Hum Mol Genet 2008, 17:1076-1086.
25. Quinlan K.G.R., Seto J.T., Turner N., Vandebrouck A., Floetenmeyer M., Macarthur D.G., et al. Alpha-actinin-3 deficiency results in reduced glycogen phosphorylase activity and altered calcium handling in skeletal muscle. Hum Mol Genet 2010, 19:1335-1346.
26. Walsh S., Liu D., Metter E.J., Ferrucci L., Roth S.M. ACTN3 genotype is associated with muscle phenotypes in women across the adult age span. J Appl Physiol (Bethesda, Md: 1985) 2008, 105:1486-1491.
27. Zempo H., Tanabe K., Murakami H., Iemitsu M., Maeda S., Kuno S. ACTN3 polymorphism affects thigh muscle area. Int J Sports Med 2010, 31:138-142.
28. Murshid S.A., Kamioka H., Ishihara Y., Ando R., Sugawara Y., Takano-Yamamoto T. Actin and microtubule cytoskeletons of the processes of 3D-cultured MC3T3-E1 cells and osteocytes. J Bone Miner Metab 2007, 25:151-158.
29. Jackson W.M., Jaasma M.J., Baik A.D., Keaveny T.M. Over-expression of alpha-actinin with a GFP fusion protein is sufficient to increase whole-cell stiffness in human osteoblasts. Ann Biomed Eng 2008, 36:1605-1614.
30. Jackson W.M., Jaasma M.J., Tang R.Y., Keaveny T.M. Mechanical loading by fluid shear is sufficient to alter the cytoskeletal composition of osteoblastic cells. Am J Physiol Cell Physiol 2008, 295:C1007-C1015.
31. Izaguirre G., Aguirre L., Hu Y.P., Lee H.Y., Schlaepfer D.D., Aneskievich B.J., et al. The cytoskeletal/non-muscle isoform of alpha-actinin is phosphorylated on its actin-binding domain by the focal adhesion kinase. J Biol Chem 2001, 276:28676-28685.
32. Triplett J.W., Pavalko F.M. Disruption of alpha-actinin-integrin interactions at focal adhesions renders osteoblasts susceptible to apoptosis. Am J Physiol Cell Physiol 2006, 291:C909-C921.
33. Seto J.T., Chan S., Turner N., MacArthur D.G., Raftery J.M., Berman Y.D., et al. The effect of α-actinin-3 deficiency on muscle aging. Exp Gerontol 2011, 46:292-302.
34. Prince R.L., Devine A., Dhaliwal S.S., Dick I.M. Effects of calcium Supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006, 166:869-875.
35. Nguyen N.D., Ahlborg H.G., Center J.R., Eisman J.A., Nguyen T.V. Residual lifetime risk of fractures in women and men. J Bone Miner Res 2007, 22:781-788.
36. Sato K., Suematsu A., Nakashima T., Takemoto-Kimura S., Aoki K., Morishita Y., et al. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med 2006, 12:1410-1416.
37. Smerdel-Ramoya A., Zanotti S., Stadmeyer L., Durant D., Canalis E. Skeletal overexpression of connective tissue growth factor impairs bone formation and causes osteopenia. Endocrinology 2008, 149:4374-4381.
38. Ermakov S., Toliat M.R., Cohen Z., Malkin I., Altmuller J., Livshits G., et al. Association of ALPL and ENPP1 gene polymorphisms with bone strength related skeletal traits in a Chuvashian population. Bone 2010, 46:1244-1250.
39. Zhou H.-D., Bu Y.-H., Huang Q.-X., Tang L.-L., Liao E.-Y. Insulin receptor substrate 2 plays important roles in 17 beta -estradiol induced bone formation. Bone 2008, 43:S97.
40. Villuendas G., Botella-Carretero J.I., Roldan B., Sancho J., Escobar-Morreale H.F., San Millan J.L. Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. Hum Reprod (Oxford, England) 2005, 20:3184-3191.
41. Salcedo A., Mayor F., Penela P. Mdm2 is involved in the ubiquitination and degradation of G-protein-coupled receptor kinase 2. EMBO J 2006, 25:4752-4762.
42. DeCarlo A.A., Grenett H., Park J., Balton W., Cohen J., Hardigan P. Association of gene polymorphisms for plasminogen activators with alveolar bone loss. J Periodontal Res 2007, 42:305-310.
43. Koga T., Matsui Y., Asagiri M., Kodama T., de Crombrugghe B., Nakashima K., et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med 2005, 11:880-885.
44. de Crombrugghe B., Lefebvre V., Behringer R.R., Bi W., Murakami S., Huang W. Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol 2000, 19:389-394.
45. Kubota T., Michigami T., Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab 2009, 27:265-271.
46. Timms A.E., Zhang Y., Russell R.G.G., Brown M.A. Genetic studies of disorders of calcium crystal deposition. Rheumatology (Oxford) 2002, 41:725-729.
47. Harmey D., Hessle L., Narisawa S., Johnson K.A., Terkeltaub R., Millan J.L. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp 1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004, 164:1199-1209.
48. Babij P., Roudier M., Graves T., Han C.Y., Chhoa M., Li C.M., et al. New variants in the Enpp 1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification. J Bone Miner Res 2009, 24:1552-1564.
49. Murthy R.K., Morrow P.K., Theriault R.L. Bone biology and the role of the RANK ligand pathway. Oncology (Williston Park, N Y) 2009, 23:9-15.
50. Yamazaki H., Sasaki T. Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice. J Electron Microsc (Tokyo) 2005, 54:467-477.
51. Stolina M., Dwyer D., Ominsky M.S., Corbin T., Van G., Bolon B., et al. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol (Baltimore, Md: 1950) 2007, 179:7497-7505.
52. Whyte M.P., Mumm S. Heritable disorders of the RANKL/OPG/RANK signaling pathway. J Musculoskelet Neuronal Interact 2004, 4:254-267.
53. Hu H., Hilton M.J., Tu X., Yu K., Ornitz D.M., Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development (Cambridge, England) 2005, 132:49-60.